Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD TSXV Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2025-04-11 Regulatory Filings
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
52-109F1R - Certification of refiled annual filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a formal certification (Form 52-109FV1R) of refiled annual financial statements and MD&A under Canadian NI 52-109 for a venture issuer. It is not the annual report itself, nor an announcement that the report is attached; rather it is a regulatory certificate filing required by securities legislation. It does not fit any specific category for financial reports, governance, capital actions, or earnings releases, so it falls into the fallback “Regulatory Filings” category.
2025-04-11 English
52-109F1R - Certification of refiled annual filings - CEO (F).pdf
Regulatory Filings Classification · 1% confidence The document is a CEO attestation under Canadian NI 52-109 regarding the issuer’s annual financial statements and MD&A for the fiscal year ending July 31, 2024. It is not the annual report itself (10-K) nor an auditor’s opinion, nor an announcement of a board change or dividend. It constitutes a specific regulatory filing (a management certification) required by securities regulators and does not fit into other more specific categories, so it defaults to Regulatory Filings (RNS).
2025-04-11 French
52-109F1R - Certification of refiled annual filings - CFO (F).pdf
Regulatory Filings Classification · 1% confidence The document is a CFO’s statutory attestation under Canadian Regulation 52-109 regarding the re-filing of annual financial statements and MD&A for the year ended July 31, 2024. It is not the annual report itself (10-K/Annual Report), nor is it MD&A, a presentation, or audit report. It is a compliance certificate filed as part of regulatory reporting—a general regulatory filing without a more specific category. Therefore, it best fits the fallback “Regulatory Filings” category (RNS).
2025-04-11 French
Annual MD&A (amended) - English.pdf
Management Reports Classification · 1% confidence The document is titled ‘Management’s Discussion and Analysis for the year ended July 31, 2024 and the quarter ended July 31, 2024,’ providing detailed narrative sections on financial results, adjustments, restatements, operations, risk management, outlook, and company activities. This corresponds precisely to a standalone MD&A report, which falls under ‘Management Reports’ (MDA).
2025-04-11 English
Annual MD&A (amended) - French.pdf
Management Reports Classification · 1% confidence The document is the Management’s Discussion & Analysis (“rapport de gestion”) for the year ended July 31, 2024 (including the quarter ended July 31, 2024). It contains narrative sections on forward-looking statements, company profile, financial highlights, R&D updates, and restated financial tables. This matches the definition of a Management Report (MDA) rather than an earnings release, annual report cover-to-cover, or simple announcement.
2025-04-11 French
Audited annual financial statements (amended) - French.pdf
Audit Report / Information Classification · 1% confidence The document is a standalone auditor’s report by PwC detailing the independent auditor’s opinion, scope of audit, key audit matters, auditor and management responsibilities, and other audit-specific disclosures for the consolidated financial statements for the years ended July 31, 2024 and 2023. It is not an annual report (10-K), earnings release, management discussion, or simply an announcement of publication, but rather the full audit report. Therefore, it fits the Audit Report / Information category. FY 2024
2025-04-11 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.